FDA Hosts Virtual Meeting on Tracking Food by the Lot Number
Published Date: 5/28/2026
Notice
Summary
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Faster Recalls and Fewer Foodborne Illnesses
FDA states that lot-level tracking enables rapid tracing of contaminated foods during recalls, allowing the Agency to find sources faster, narrow recall scope, and remove affected products quickly, which results in fewer foodborne illnesses and deaths.
Enforcement Pause Through July 20, 2028
Congress directed FDA not to enforce the Food Traceability Rule prior to July 20, 2028 (Continuing Appropriations Act, Pub. L. 119-37). The original compliance date had been January 20, 2026 and FDA had proposed extending compliance to July 20, 2028.
Lot-Level Tracking Recordkeeping Requirement
The Food Traceability Rule requires businesses that manufacture, process, pack, or hold foods on FDA's Food Traceability List to assign unique Traceability Lot Codes that must be passed along unchanged (unless transformed) and to record Key Data Elements (KDEs) when performing Critical Tracking Events (CTEs) such as initial packing, transformation, and shipping.
FDA Stakeholder Meeting and Comment Opportunity
FDA will hold a virtual public meeting on June 15, 2026 (12:00-3:30 p.m. ET) to discuss lot-level traceability; registration is open until June 14, 2026 and speakers must register by June 5, 2026. Electronic or written comments on the meeting or the discussion paper are due by July 15, 2026 (comments accepted via https://www.regulations.gov until 11:59 p.m. ET on July 15, 2026).
Congressional Directive for Quarterly Engagement and 180‑Day Recommendations
Section 780 of the Continuing Appropriations Act directed FDA to engage quarterly with regulated entities to identify and implement, as appropriate, additional flexibilities for satisfying the Rule’s lot-level tracking requirement and said FDA should provide industry stakeholders with recommendations within 180 days of the Act's enactment.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10621 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss
The FDA is officially classifying the endoscopic suturing device for weight loss as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative tool faster and ensures it’s safe and effective. The new rules took effect on May 28, 2026, and could save time and money for makers and users alike.
2026-10615 — Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove four harmful solvents—benzene, ethylene dichloride, methylene chloride, and trichloroethylene—from food additive rules. This change affects food makers who use these solvents and aims to make our food safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any costly changes happen.
2026-10614 — Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove three harmful solvents—ethylene dichloride, methylene chloride, and trichloroethylene—from color additive rules. This change affects companies using these solvents in color additives and aims to make products safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any final decisions.
2026-10479 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
The FDA just announced that certain estrogen-androgen combo drugs, like Syntest D.S. and Syntest H.S., aren’t proven effective and can’t be sold unless they have official approval. This affects drug makers and sellers who must stop interstate shipments of these products by June 26, 2026. If you’re involved, it’s time to get compliant or say goodbye to these meds on the market!
2026-10372 — Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
The FDA wants your thoughts on how they collect info about making custom human drugs under special rules (Sections 503A and 503B). This affects pharmacies and drug makers who mix medicines just for patients. You’ve got until July 27, 2026, to share your comments—no cost changes yet, just a chance to help shape the paperwork process!
2026-10371 — Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal
The FDA is renewing its Drug Safety and Risk Management Advisory Committee for two more years, keeping it active until May 31, 2028. This committee helps the FDA make smart decisions about drug safety and risks, protecting everyone who uses medicines. No new costs or big changes, just a continued commitment to keeping drugs safe and sound.
Previous / Next Documents
Previous: 2026-10602 — AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information; Extension of Comment Period
The FDA is giving people more time to share their thoughts on a new pilot program that uses AI to make early clinical trials faster and smarter. This program could help researchers make better decisions and speed up how new medicines are tested. If you want to weigh in, you now have until June 29, 2026, to send your comments—no money changes yet, but this could shake up how trials run in the future!
Next: 2026-10605 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Title-Student Volunteer Service Agreement
The Drug Enforcement Administration wants to keep using a form that helps students, schools, and the agency agree on volunteer work rules. They’re asking for public feedback by July 27, 2026, to make sure the form is clear and easy to use without causing extra hassle. This keeps things smooth for student volunteers and the agency, with no new costs involved.